To: tuck who wrote (649 ) 1/23/2001 9:48:49 AM From: tuck Read Replies (1) | Respond to of 712 CORR reports earnings:biz.yahoo.com >>SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Jan. 23, 2001--COR Therapeutics, Inc. (Nasdaq:CORR - news) announced today that worldwide sales of INTEGRILIN® (eptifibatide) Injection were $171,700,000 for the year 2000, as reported to COR by its partner for INTEGRILIN, Schering-Plough Corporation. Sales for the fourth quarter of 2000 were $50,400,000, up 155% from $19,800,000 reported for the fourth quarter of 1999. The Company reported copromotion revenue of $29,218,000 for the fourth quarter of 2000 related to the sales of INTEGRILIN by Schering-Plough, compared to $11,309,000 for the fourth quarter of 1999. COR reported a net income of $0.02 per share for the fourth quarter of 2000, compared to a net loss of $0.11 per share for the fourth quarter of 1999. COR also reported total contract revenues for 2000 of $104,741,000, compared to $56,658,000 for 1999. The net loss for 2000 was $16,651,000, or $0.31 per share, compared to a net loss of $26,070,000, or $0.53 per share for 1999. As of December 31, 2000, COR had cash, cash equivalents and short-term investments of $339,878,000. COR also stated that it would webcast a conference call live at 10:00 a.m. Eastern Standard Time, today, January 23, 2001, as part of the Company's efforts to ensure full disclosure to all parties. Access to the live call or the 7-day archive is provided via the Company's internet site, corr.com . Alternatively, the webcast may be accessed by logging on to vcall.com . Please connect to either website at least 10 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the live webcast.<< snip Cheers, Tuck